UK markets closed

Oxford BioMedica plc (OXB.L)

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
172.00-0.20 (-0.12%)
At close: 05:10PM GMT
Full screen
Previous close172.20
Open179.80
Bid168.40 x 0
Ask170.40 x 0
Day's range168.40 - 179.80
52-week range164.29 - 575.00
Volume306,333
Avg. volume302,779
Market cap173.044M
Beta (5Y monthly)1.00
PE ratio (TTM)N/A
EPS (TTM)-0.64
Earnings date23 Apr 2024 - 29 Apr 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est425.25
  • GlobeNewswire

    Oxford Biomedica completes acquisition of ABL Europe

    Oxford Biomedica completes acquisition of ABL Europe Strengthens Oxford Biomedica’s position as a global pure-play cell and gene therapy CDMO with multi viral vector capabilities across multiple sites in EU, US and UKExpands Oxford Biomedica’s ability to serve more clients, unlocking development capacity and increasing revenues3.2 per cent of the Company’s share capital issued to Institut Mérieux at a share price of 407.4p Oxford, UK – 29 January 2024: Oxford Biomedica plc (LSE:OXB) (“Oxford Bio

  • Globe Newswire

    Oxford Biomedica is hosting a free webinar to share clients’ success stories in viral vector manufacturing

    Oxford Biomedica is hosting a free webinar to share clients’ success stories in viral vector manufacturing Oxford, UK – 23 January 2024: On Wednesday 7 February, Oxford Biomedica, a quality and innovation-led cell and gene therapy CDMO, will host a free 60-minute webinar offering an in-depth view of the customer journey from client onboarding to the successful manufacture of adeno-associated virus and lentiviral vectors.. This event will demonstrate how unique and transferable technical expertis

  • Simply Wall St.

    Oxford Biomedica (LON:OXB) shareholders have endured a 79% loss from investing in the stock three years ago

    As an investor, mistakes are inevitable. But really bad investments should be rare. So take a moment to sympathize with...